Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of rapamycin

Ha Na Woo, Won Il Lee, Ji Hyun Kim, Jeonghyun Ahn, Jeong Hee Han, Sue Yeon Lim, Won Woo Lee, Heuiran Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A proof-of-concept study is presented using dual gene therapy that employed a small hairpin RNA (shRNA) specific for mammalian target of rapamycin (mTOR) and a herpes simplex virus-thymidine kinase (HSV-TK) gene to inhibit the growth of tumors. Recombinant adeno-associated virus (rAAV) vectors containing a mutant TK gene (sc39TK) were transduced into HeLa cells, and the prodrug ganciclovir (GCV) was administered to establish a suicide gene-therapy strategy. Additionally, rAAV vectors expressing an mTORtargeted shRNA were employed to suppress mTOR-dependent tumor growth. GCV selectively induced death in tumor cells expressing TK, and the mTOR-targeted shRNA altered the cell cycle to impair tumor growth. Combining the TK-GCV system with mTOR inhibition suppressed tumor growth to a greater extent than that achieved with either treatment alone. Furthermore, HSV-TK expression and mTOR inhibition did not mutually interfere with each other. In conclusion, gene therapy that combines the TK-GCV system and mTOR inhibition shows promise as a novel strategy for cancer therapy.

Original languageEnglish (US)
Pages (from-to)2233-2239
Number of pages7
JournalInternational Journal of Oncology
Volume47
Issue number6
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Thymidine Kinase
Simplexvirus
Sirolimus
Genetic Therapy
Small Interfering RNA
Ganciclovir
Neoplasms
Dependovirus
Growth
Prodrugs
HeLa Cells
Suicide
Genes
Cell Cycle
Therapeutics
Inhibition (Psychology)

Keywords

  • Mammalian target of rapamycin
  • Recombinant adenoassociated virus
  • Small hairpin RNA
  • Suicide gene therapy
  • Thymidine kinase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of rapamycin. / Woo, Ha Na; Lee, Won Il; Kim, Ji Hyun; Ahn, Jeonghyun; Han, Jeong Hee; Lim, Sue Yeon; Lee, Won Woo; Lee, Heuiran.

In: International Journal of Oncology, Vol. 47, No. 6, 01.12.2015, p. 2233-2239.

Research output: Contribution to journalArticle

Woo, Ha Na ; Lee, Won Il ; Kim, Ji Hyun ; Ahn, Jeonghyun ; Han, Jeong Hee ; Lim, Sue Yeon ; Lee, Won Woo ; Lee, Heuiran. / Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of rapamycin. In: International Journal of Oncology. 2015 ; Vol. 47, No. 6. pp. 2233-2239.
@article{546b4a21627c4f0387db975b31ea672a,
title = "Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of rapamycin",
abstract = "A proof-of-concept study is presented using dual gene therapy that employed a small hairpin RNA (shRNA) specific for mammalian target of rapamycin (mTOR) and a herpes simplex virus-thymidine kinase (HSV-TK) gene to inhibit the growth of tumors. Recombinant adeno-associated virus (rAAV) vectors containing a mutant TK gene (sc39TK) were transduced into HeLa cells, and the prodrug ganciclovir (GCV) was administered to establish a suicide gene-therapy strategy. Additionally, rAAV vectors expressing an mTORtargeted shRNA were employed to suppress mTOR-dependent tumor growth. GCV selectively induced death in tumor cells expressing TK, and the mTOR-targeted shRNA altered the cell cycle to impair tumor growth. Combining the TK-GCV system with mTOR inhibition suppressed tumor growth to a greater extent than that achieved with either treatment alone. Furthermore, HSV-TK expression and mTOR inhibition did not mutually interfere with each other. In conclusion, gene therapy that combines the TK-GCV system and mTOR inhibition shows promise as a novel strategy for cancer therapy.",
keywords = "Mammalian target of rapamycin, Recombinant adenoassociated virus, Small hairpin RNA, Suicide gene therapy, Thymidine kinase",
author = "Woo, {Ha Na} and Lee, {Won Il} and Kim, {Ji Hyun} and Jeonghyun Ahn and Han, {Jeong Hee} and Lim, {Sue Yeon} and Lee, {Won Woo} and Heuiran Lee",
year = "2015",
month = "12",
day = "1",
doi = "10.3892/ijo.2015.3194",
language = "English (US)",
volume = "47",
pages = "2233--2239",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Combined antitumor gene therapy with herpes simplex virus-thymidine kinase and short hairpin RNA specific for mammalian target of rapamycin

AU - Woo, Ha Na

AU - Lee, Won Il

AU - Kim, Ji Hyun

AU - Ahn, Jeonghyun

AU - Han, Jeong Hee

AU - Lim, Sue Yeon

AU - Lee, Won Woo

AU - Lee, Heuiran

PY - 2015/12/1

Y1 - 2015/12/1

N2 - A proof-of-concept study is presented using dual gene therapy that employed a small hairpin RNA (shRNA) specific for mammalian target of rapamycin (mTOR) and a herpes simplex virus-thymidine kinase (HSV-TK) gene to inhibit the growth of tumors. Recombinant adeno-associated virus (rAAV) vectors containing a mutant TK gene (sc39TK) were transduced into HeLa cells, and the prodrug ganciclovir (GCV) was administered to establish a suicide gene-therapy strategy. Additionally, rAAV vectors expressing an mTORtargeted shRNA were employed to suppress mTOR-dependent tumor growth. GCV selectively induced death in tumor cells expressing TK, and the mTOR-targeted shRNA altered the cell cycle to impair tumor growth. Combining the TK-GCV system with mTOR inhibition suppressed tumor growth to a greater extent than that achieved with either treatment alone. Furthermore, HSV-TK expression and mTOR inhibition did not mutually interfere with each other. In conclusion, gene therapy that combines the TK-GCV system and mTOR inhibition shows promise as a novel strategy for cancer therapy.

AB - A proof-of-concept study is presented using dual gene therapy that employed a small hairpin RNA (shRNA) specific for mammalian target of rapamycin (mTOR) and a herpes simplex virus-thymidine kinase (HSV-TK) gene to inhibit the growth of tumors. Recombinant adeno-associated virus (rAAV) vectors containing a mutant TK gene (sc39TK) were transduced into HeLa cells, and the prodrug ganciclovir (GCV) was administered to establish a suicide gene-therapy strategy. Additionally, rAAV vectors expressing an mTORtargeted shRNA were employed to suppress mTOR-dependent tumor growth. GCV selectively induced death in tumor cells expressing TK, and the mTOR-targeted shRNA altered the cell cycle to impair tumor growth. Combining the TK-GCV system with mTOR inhibition suppressed tumor growth to a greater extent than that achieved with either treatment alone. Furthermore, HSV-TK expression and mTOR inhibition did not mutually interfere with each other. In conclusion, gene therapy that combines the TK-GCV system and mTOR inhibition shows promise as a novel strategy for cancer therapy.

KW - Mammalian target of rapamycin

KW - Recombinant adenoassociated virus

KW - Small hairpin RNA

KW - Suicide gene therapy

KW - Thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=84982703178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982703178&partnerID=8YFLogxK

U2 - 10.3892/ijo.2015.3194

DO - 10.3892/ijo.2015.3194

M3 - Article

C2 - 26459571

AN - SCOPUS:84982703178

VL - 47

SP - 2233

EP - 2239

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -